7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

1/15

for prostate ca

Biotechnological medicin

in developm

Georgios LavasidisMedical student at the

University of Ioannina

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

2/15

Epidemiology

Prostate Cancer (C61): 2008 Estimates

European Age-Standardised Incidence Rates per 100,000 population, Males, EU27 Countries

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

3/15

Epidemiology

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

4/15

Cellular immunotherapy

Date of approval():

6/9/2013

sipuleucel-T

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

5/15

Medicines in development

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

6/15

Clinical trials: Phase/Ia

REIC (Reduced Expression inImmortalized Cells): tumorsuppressor gene

Forced gene expression usingadenoviral vector

REIC gene therapy

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

7/15

REIC gene therapy

Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous c

vaccination therapy (Review), Watanabe et al., Oncol Lett. Mar 2014; 7(3): 595

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

8/15

REIC gene therapy

Preclinical safety and efficacy of in situ REIC/Dkk-3 gene therapy for prostate

cancer, Kawauchi et al., Acta Med Okayama. 2012;66(1):7-16

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

9/15

Antisense RNAs: RNAs that bind to complementary m

inhibit their translation

LNA-based oligonucleotide that targets the androgen(AR)

The expression of AR is increased in some prostate cand is related to proliferation and survival of cancer

Androgen receptor antisense oligonucleo(EZN-4176)

LNA monomer: The bridge between the

2'-

and the 4'-C enhances the stabilityof the molecule

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

10/15

LNA

(AR Gene)

[Clinical tria

Androgen receptor antisense oligonucleo(EZN-4176)

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

11/15

(Control)

(Control)

Reduced expression of the androgen receptor by third generation of antisen

shows antitumor activity in models of prostate cancer, Zhang et al., Mol Can

Ther. 2011 Dec;10(12):2309-19

[Preclinical tria

Androgen receptor antisense oligonucleo(EZN-4176)

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

12/15

Clinical trials: Phase

Metastatic castration-resistant prostate Ca

Pox-viruses

PSA-TRICOM vaccine

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

13/15

PSA-TRICOM vaccine

Overall survival analysis of a phase II randomized controlled trial of a Poxvira

based PSA-targeted immunotherapy in metastatic castration-resistant prosta

cancer, Kantoff PW et al., J Clin Oncol. 2010 Mar 1;28(7):1099-105

Phase II RCT

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

14/15

Medicine Type Development st

anti-STEAP1 ADC mAb-drug conjugate Clinical trials: Ph

rilotumumab mAb Clinical trials: Ph

anti-integrin mAb mAb Clinical trials: Ph

ipilimumab mAb Clinical trials: Ph

nelipepmut-S peptide vaccine Clinical trials: Ph

BPX-101 dendritic cell vaccine Clinical trials: Ph

GVAX-PCa immunotherapeutic vaccine Clinical trials: Ph

TeloB-Vax telomerase cancer

vaccine

DNA vaccine Clinical trials: Ph

AdV-tk + valacyclovir gene therapy Clinical trials: Ph

Other possible medicines

7/24/2019 Biotechnological Medicines in Development for Prostate Cancer

15/15